Neuroptika Completes Patient Enrollment for Phase 2 Dry Eye Disease Trial

Neuroptika has officially completed patient enrollment for its Phase 2 clinical trial investigating NRO-1, a novel therapeutic candidate for dry eye disease. This multicenter, randomized, and double-masked study aims to assess both the safety and efficacy of the treatment in 124 participants. The trial focuses on individuals suffering from moderate-to-severe forms of the condition, including those who have recently undergone ocular surgery. By targeting the regeneration of corneal nerves, the drug represents a potential shift toward disease-modifying therapies rather than just symptom management. Tim Min, the Chief Executive Officer of Neuroptika, stated that the company is pleased to reach this milestone and looks forward to progressing the development of the treatment. He noted that NRO-1 may provide physicians and patients with a significantly better option for managing the chronic condition. The study compares two different concentrations of the drug against a vehicle control over a 28-day treatment period. Researchers are utilizing a variety of metrics to evaluate the drug's performance, including standard clinical signs and symptoms associated with dry eye. Additionally, the trial incorporates advanced nerve morphology imaging and biomarker analysis to track physiological changes in the eye. These detailed endpoints are intended to provide a comprehensive view of how the therapy interacts with corneal tissue. The company expressed gratitude to the patients, investigators, and the internal team for their efforts in completing the enrollment phase. Following the conclusion of the dosing period, the research team will begin a thorough analysis of the collected data. Neuroptika plans to report the topline results from this study in the fourth quarter of 2026. If successful, the findings could pave the way for larger, late-stage clinical trials to further validate the drug's potential. This development is part of a broader effort in the ophthalmic field to address the underlying causes of ocular surface diseases.